GlassScriptPhysician profile
Ryan P Griffin
NPI 1619276516
$8,385.98
in general payments reported to CMS, 2019-2025
43 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2021: $453 · 2022: $1,289 · 2023: $614 · 2024: $3,574 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261 · Consulting Fee: $1,925 · Education: $79.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,260.56 |
| Consulting Fee | $1,925.00 |
| Education | $79.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,488.46 | 2021-2025 | Lynparza, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,382.68 | 2022-2025 | Talvey, Rybrevant, Darzalex |
| Merck Sharp & Dohme LLC | $802.85 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Beigene USA, INC. | $712.20 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $454.92 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $423.54 | 2021-2025 | |
| Astellas Pharma US INC | $300.12 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Genentech USA, INC. | $250.51 | 2019-2025 | Polivy, Venclexta, Tecentriq Hybreza |
| Sobi, INC | $222.59 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $198.70 | 2021-2025 | Ultomiris |
| Pfizer INC. | $193.00 | 2024-2025 | |
| Genzyme Corporation | $192.15 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.17 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Exelixis INC. | $133.14 | 2023-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $119.56 | 2024-2025 | Monoferric, Cosela |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.